Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer
-
Gesprochen von:
-
Von:
Über diesen Titel
We are pleased to present Part 1 of an exclusive podcast, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.
Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer.
Topics include:
- The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment of early-stage HR-positive/HER2-negative breast cancer
- Long-term outcomes of CDK4/6 inhibitors including new 7-year data from the monarchE trial and 5-year data from the NATALEE trial
Discussants:
Neil M. Iyengar, MD
Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Seth Wander, MD, PhD
Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA
Sponsored by Lilly
